This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
pharmaceuticals: Archive
Pfizer Targets Long-Term Oncology Growth Amid Competitive Pressure
by Kinjel Shah
PFE's oncology sales rose 8% in 2025 as Padcev, Lorbrena and new launches offset Ibrance declines.
AZNPositive Net Change JNJPositive Net Change PFEPositive Net Change MRKPositive Net Change
pharmaceuticals
ImmunityBio Wins EU Nod for Bladder Cancer Combo Therapy, Stock Up
by Zacks Equity Research
IBRX wins conditional EU approval for its Anktiva+BCG bladder cancer combo, sending shares soaring 41.9% and expanding its global footprint to 33 countries.
ALKSNegative Net Change CSTLNegative Net Change HRMYNegative Net Change IBRXPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
EU Approves Novo Nordisk's Higher-Dose Wegovy for Obesity Patients
by Zacks Equity Research
NVO wins EU nod for a higher 7.2 mg Wegovy dose, unlocking stronger weight-loss results and a new step-up option for obesity care.
NVONegative Net Change ALKSNegative Net Change CSTLNegative Net Change HRMYNegative Net Change
biotechnology biotechs medical pharmaceuticals
Should Investors Buy, Sell or Hold KROS Stock Ahead of Q4 Earnings?
by Zacks Equity Research
KROS investors eye pipeline updates as rinvatercept advances in DMD and Takeda-backed elritercept hits milestones ahead of Q4 results.
SRPTNegative Net Change TAKPositive Net Change KROSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Cytokinetics Wins EU Approval for Cardiovascular Drug Myqorzo
by Zacks Equity Research
CYTK secures EU approval for Myqorzo in symptomatic obstructive HCM, expanding its first commercial drug across major global markets.
BMYPositive Net Change ALKSNegative Net Change CYTKNegative Net Change HRMYNegative Net Change
biotechnology biotechs medical pharmaceuticals
Will Tavalisse Continue to Drive Rigel Pharmaceuticals' Growth in 2026?
by Sundeep Ganoria
RIGL's 2025 sales jump 60% to $232M, led by Tavalisse. With 2026 product sales seen at $255-$265M, can its momentum withstand rising competition?
SNYPositive Net Change LLYPositive Net Change RIGLNegative Net Change
biotechs medical pharmaceuticals
Can LLY's Next-Gen Obesity Pipeline Sustain Growth Amid Competition?
by Kinjel Shah
Lilly is advancing next-gen obesity drugs like oral orforglipron and retatrutide as competition heats up.
NVONegative Net Change LLYPositive Net Change VKTXPositive Net Change GPCRNegative Net Change
pharmaceuticals
Top 5 Bargain P/B Stocks Investors Should Watch Now
by Kinjel Shah
AES joins four other low P/B stocks that screen for value, growth and liquidity, offering investors undervalued picks to watch in February.
AESPositive Net Change GPNNegative Net Change CNXCPositive Net Change HRMYNegative Net Change PAXNegative Net Change
pharmaceuticals
Top Analyst Reports for AbbVie, RTX & IBM
by Mark Vickery
AbbVie leads today's top analyst picks after beating Q4 estimates, while RTX and IBM also draw attention for strong results and growth drivers.
GEPositive Net Change WMBNegative Net Change IBMNegative Net Change DBNegative Net Change ABBVPositive Net Change RMCFNegative Net Change EVINegative Net Change RTXPositive Net Change
aerospace computers industrial-products pharmaceuticals restaurants
Can BMY's Growth Portfolio Counter Legacy Drugs Decline in 2026?
by Ekta Bagri
BMYs 2025 results highlight a shifting revenue mix as 17% growth in newer drugs offsets legacy declines, with more erosion expected in 2026.
BMYPositive Net Change MRKPositive Net Change CYTKNegative Net Change
biotechnology biotechs medical pharmaceuticals